Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 6, 2017
Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...
Mar 16, 2017
- Second Phase 2 study for ACE-083 expected to begin 2H 2017 - - Company to host educational webinar with leading clinical researcher on April 3rd at 11:00 a.m. EDT - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Mar 1, 2017
- Luspatercept Phase 3 trials to complete enrollment in both the MDS ("MEDALIST") and beta-thalassemia ("BELIEVE") trials in 2H 2017 - - Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December - - Treated f...
Feb 28, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Feb 22, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webca...
Feb 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Jan 6, 2017
- Luspatercept MEDALIST Phase 3 trial in MDS expected to complete enrollment in the 2nd half of 2017 - - Luspatercept BELIEVE Phase 3 trial in beta-thalassemia expected to complete enrollment in the 2nd half of 2017 - - Plan to initiate new luspatercept Phase 2 clinical trials in ...
Jan 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, wil...
Dec 22, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the first patient has been treated in a Phase 2 clinic...
Dec 5, 2016
- Interim longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, and reduced transfusion burden in patients with beta-thalassemia - CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN) and Celg...
Dec 5, 2016
- Preliminary results show that treatment with investigational drug sotatercept can increase hemoglobin and achieve transfusion independence in patients with myelofibrosis - - Acceleron to host conference call and live webcast on Monday, December 5th at 9:00 a.m. EST (6:00 a.m. PST) - ...
Dec 4, 2016
- Preliminary results show that treatment with investigational drug luspatercept increases hemoglobin and achieves durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Preliminary data in ESA naïve and RS- patients are encouraging - - Acce...
Nov 30, 2016
- Management to review highlights from luspatercept and sotatercept clinical presentations - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative t...
Nov 3, 2016
- Appointed Habib Dable as President and CEO effective December 1, 2016 - - Five upcoming presentations at American Society of Hematology Annual Meeting in December - - Advancing ACE-083 into Phase 2 study for facioscapulohumeral muscular dystrophy (FSHD) - ...
Nov 3, 2016
- Oral and poster presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia and myelofibrosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, developme...
Page:
...
Next Last
 
= add release to Briefcase